RLYB

NASDAQ 已收盘

Rallybio

15.47 USD
▼-0.05-0.32%
盘后 15.60 +0.84%
2026-11-20
市值
$83.29M
市盈率
3.33
EPS
4.65
股息率
—
52 周区间
3.67 – 17.57
成交量
51.61K
Beta
-0.77
目标价
—
52W 低 3.6752W 高 17.57
价格走势

公司简介

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to ...